THERAPY DOSSIER · th-80e5909dad38

Multipotent adult progenitor cells (MAPCs)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT01841632 ↗PHASE1terminated

Safety and feasibility of multipotent adult progenitor cells (MultiStem) for immunomodulation therapy after liver transplantation (MiSOT Phase I)

Liver Transplantation

Enrolment: 3 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24191266 ↗2013Reported benefit

Intravenous multipotent adult progenitor cell therapy attenuates activated microglial/macrophage response and improves spatial learning after traumatic brain injury.

RatTBIControlled cortical impactmaleIntravenousTwo concentrations: 2 million cells per kilogram and 10 mil…2 hours and 24 hours after cortical contusion injury

Model: Controlled cortical impact traumatic brain injury

At 120 days after injury the high dose group (10 million cells per kilogram) showed significant improvement in left hind limb deficit on the balance beam, decreased latency to platform and distance travelled on day 5 of Morris water maze testing, and decreased proximity measure on probe trials indi…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…